Stock NOVA NOVA MENTIS LIFE SCIENCE CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Nova Mentis Life Science Corp.

Equities

NOVA

CA66980V1067

Market Closed - Canadian Securities Exchange
Other stock markets
 20:38:53 25/04/2024 BST 		5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for Nova Mentis Life Science Corp. +50.00% -25.00%
04-08 Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-26 Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors
Nova Mentis Life Science Corp. Announces Management Changes
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nova Mentis Life Science Corp.: Nova Mentis begrüßt Entscheidung der Regierung zur Einrichtung einer Beratergruppe für seltene Krankheiten
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Nova Mentis Life Science Corp. Announces Board Changes
Nova Mentis Receives Health Canada Approval for First-Of-its-Kind Psilocybin Clinical Trial
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Nova Mentis Enters into Research Services Contract with KGK Science for Phase II A Clinical Trial
Nova Mentis Life Science Corp. Produces 1.5 mg Psilocybin Microdose Capsules
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NOVA Stock
  4. News Nova Mentis Life Science Corp.
  5. Other languages